Rezolute is trading 9.98% up at $5.12, but no clear company-specific catalyst was identified for August 21, 2026.
- The latest identifiable update remains June 2’s positive interim upLIFT data.
- Fully enrolled topline results are expected during the second half of 2026, but that announcement is not timely enough to establish today’s cause.
- Biotech-sector weakness does not explain the gain, leaving the catalyst unclear.